share_log

Evercore ISI Group Upgrades NovoCure to Outperform, Raises Price Target to $30

Evercore ISI Group Upgrades NovoCure to Outperform, Raises Price Target to $30

evercore ISI集团将novocure的评级上调至跑赢大市,并将目标价提高至30美元。
Benzinga ·  2024/12/02 19:50  · 评级/大行评级

Evercore ISI Group analyst Vijay Kumar upgrades NovoCure (NASDAQ:NVCR) from In-Line to Outperform and raises the price target from $18 to $30.

Evercore ISI集团分析师维杰·库马尔将NovoCure(纳斯达克股票代码:NVCR)从In-Line上调至跑赢大盘,并将目标股价从18美元上调至30美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发